Tenaya Therapeutics, Inc.
NMS: TNYALive Quote
📈 ZcoreAI Score
Our AI model analyzes Tenaya Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get TNYA Z-Score →About Tenaya Therapeutics, Inc.
Healthcare
Biotechnology
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
📊 Fundamental Analysis
Tenaya Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -83.8%, which indicates that capital utilization is currently under pressure.
At a current price of $0.69, TNYA currently trades near the bottom of its 52-week range (17%), indicating potential value or weakness (Range: $0.36 - $2.35).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$149.73M
Trailing P/E
--
Forward P/E
-1.53
Beta (5Y)
3.00
52W High
$2.35
52W Low
$0.36
Avg Volume
4.43M
Day High
Day Low